Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Perrigo wins approval for OTC Cetirizine Oral Solution
The product will be marketed under store brand labels and is comparable to McNeil Consumer Healthcare’s children’s Zyrtec Oral Solution, 1mg/mL, indicated for indoor and outdoor allergy and
The product will be marketed under store brand labels and is comparable to McNeil Consumer Healthcare’s children’s Zyrtec Oral Solution, 1mg/mL, indicated for indoor and outdoor allergy and
Picoplatin, Poniard’s lead product candidate, is a new generation platinum agent designed to overcome platinum resistance. The development of molecular signatures of platinum resistance may allow the prediction
The Phase IIA trial is focused on assessing the safety and efficacy of the oral insulin capsule on 10 type 2 diabetes patients. This study is a continuation
In this study Apoptone inhibited the growth of androgen-independent human tumors LuCaP 35V grown subcutaneously as well as growth of C4-2B cells in the bone environment of castrated
As consideration for exclusive world-wide commercialization rights for Sublinox and OX-NLA, Meda has paid $20 million. Meda has also agreed to the one time milestone payments for each
In the NeuVax (E75) trial 163 patients with breast cancer were enrolled to determine whether the level of HER2 (human epidermal growth factor receptor 2) expression affected response.
Prior to the acquisition, Nutra Pharma owned 38.1% of ReceptoPharm. The acquisition of the remaining interest in Receptopharm provided Nutra Pharma with 100% of the outstanding ReceptoPharm stock
The agreement settles the patent infringement litigation filed by AstraZeneca following Ranbaxy’s submission to the FDA of an abbreviated new drug application for a generic version of Nexium.
The approval allows Cephalon to market Effentora in the 27 member states of the EU, as well as Iceland and Norway. Alain Aragues, president of Cephalon Europe, said:
Under its distribution agreement with Medafor, Orthovita has the non-exclusive right to sell Vitasure in the spine and orthopedic field in the US, and certain territories outside of